All In Biotech

Drug Trial Radar · NCT06552416

Safety of MT-401-OTS in Patients With Relapsed AML or MDS

A Phase 1 Study of Allogenic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cell Products (MT-401-OTS) Administered to Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes (RAPID)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jun 16, 2025

Primary completion

Sep 2029

Study completion Sep 2029

Sponsor

Lead sponsor
Marker Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
University of Kansas Medical Center; H. Lee Moffitt Cancer Center and Research Institute; City of Hope National Medical Center; FDA Office of Orphan Products Development
First posted
Aug 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 1 multicenter, open-label study evaluating the safety and efficacy of escalating doses of MT-401-OTS in 2 participant populations: 1) Those with intermediate or high-risk AML per 2022 ELN criteria who have evidence of MRD and/or \</= 10% blast following prior induction therapy or at least 4 cycles of nonintensive therapy and 2) those with high- or very-high-risk MDS per 2023 IWG criteria and who have residual disease with \</= 10% blasts following treatment with an HMA-based therapy.

Conditions

  • Acute Myeloid Leukemia, in Relapse
  • MDS

Interventions

  • MT-401-OTSDrug

    MT-401-OTS is an off the shelf cellular therapy product given by IV infusion through either a peripheral or central line.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of MT-401-OTSTime frame: Through study completion. Approximately 5 years
  2. Tolerability of MT-401-OTSTime frame: Through study completion. Approximately 5 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Center (City of Hope National Medical Center, City of Hope Medical Center)

    Duarte, California · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • KU Cancer Center

    Kansas City, Kansas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.